DE69835965T2 - CD154-BLOCKADETHERAPIE DER PANKREASINSELZELLTRANSPLANTATION bei Primaten - Google Patents

CD154-BLOCKADETHERAPIE DER PANKREASINSELZELLTRANSPLANTATION bei Primaten Download PDF

Info

Publication number
DE69835965T2
DE69835965T2 DE69835965T DE69835965T DE69835965T2 DE 69835965 T2 DE69835965 T2 DE 69835965T2 DE 69835965 T DE69835965 T DE 69835965T DE 69835965 T DE69835965 T DE 69835965T DE 69835965 T2 DE69835965 T2 DE 69835965T2
Authority
DE
Germany
Prior art keywords
insulin
antibody
tissue
cells
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69835965T
Other languages
German (de)
English (en)
Other versions
DE69835965D1 (de
Inventor
S. Norma Miami KENYON
Camillo Miami Beach RICORDI
W. David Wellesley THOMAS
Linda West Newton BURKLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
University of Miami
Biogen MA Inc
Original Assignee
University of Miami
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami, Biogen Idec Inc, Biogen Idec MA Inc filed Critical University of Miami
Application granted granted Critical
Publication of DE69835965D1 publication Critical patent/DE69835965D1/de
Publication of DE69835965T2 publication Critical patent/DE69835965T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • External Artificial Organs (AREA)
  • Steroid Compounds (AREA)
DE69835965T 1997-06-20 1998-06-19 CD154-BLOCKADETHERAPIE DER PANKREASINSELZELLTRANSPLANTATION bei Primaten Expired - Fee Related DE69835965T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US50267P 1997-06-20
US7726598P 1998-03-09 1998-03-09
US77265P 1998-03-09
PCT/US1998/012892 WO1998058669A2 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for pancreatic islet tissue transplantation

Publications (2)

Publication Number Publication Date
DE69835965D1 DE69835965D1 (de) 2006-11-02
DE69835965T2 true DE69835965T2 (de) 2007-06-14

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835965T Expired - Fee Related DE69835965T2 (de) 1997-06-20 1998-06-19 CD154-BLOCKADETHERAPIE DER PANKREASINSELZELLTRANSPLANTATION bei Primaten

Country Status (21)

Country Link
US (2) US20030072754A1 (https=)
EP (1) EP1051191B1 (https=)
JP (1) JP2002506446A (https=)
KR (1) KR100634847B1 (https=)
CN (2) CN1195546C (https=)
AT (1) ATE339966T1 (https=)
AU (1) AU730763B2 (https=)
BG (1) BG64976B1 (https=)
BR (1) BR9810620A (https=)
CA (1) CA2294154A1 (https=)
DE (1) DE69835965T2 (https=)
EA (1) EA002550B1 (https=)
EE (1) EE9900588A (https=)
HU (1) HUP0003160A3 (https=)
IL (1) IL133303A0 (https=)
IS (1) IS5273A (https=)
NO (1) NO996275L (https=)
NZ (1) NZ502052A (https=)
SK (1) SK180299A3 (https=)
TR (1) TR199903142T2 (https=)
WO (1) WO1998058669A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2410786A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
MXPA02012157A (es) * 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
EP1639014B1 (en) * 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
JP2008520235A (ja) * 2004-11-22 2008-06-19 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド インスリンを産生可能な拡大され、かつ再分化した成体島β細胞の集団およびその作製方法
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
CN102388063B (zh) 2009-02-10 2016-04-20 纽约哥伦比亚大学理事会 5c8Mab和调节性CD8+T细胞直接诱导在建立持久和特异性移植耐受中的用途
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
KR100634847B1 (ko) 2006-10-17
AU730763B2 (en) 2001-03-15
BG104091A (en) 2000-10-31
JP2002506446A (ja) 2002-02-26
ATE339966T1 (de) 2006-10-15
WO1998058669A2 (en) 1998-12-30
KR20010013965A (ko) 2001-02-26
NO996275D0 (no) 1999-12-17
WO1998058669A3 (en) 1999-04-29
IS5273A (is) 1999-11-26
HUP0003160A2 (hu) 2001-01-29
EA200000058A1 (ru) 2000-08-28
BR9810620A (pt) 2000-10-03
EE9900588A (et) 2000-08-15
BG64976B1 (bg) 2006-11-30
TR199903142T2 (xx) 2000-09-21
NZ502052A (en) 2001-01-26
AU7983098A (en) 1999-01-04
EP1051191A2 (en) 2000-11-15
EA002550B1 (ru) 2002-06-27
HUP0003160A3 (en) 2002-09-30
IL133303A0 (en) 2001-04-30
CN1195546C (zh) 2005-04-06
NO996275L (no) 2000-02-21
SK180299A3 (en) 2000-06-12
US20030072754A1 (en) 2003-04-17
HK1033548A1 (en) 2001-09-07
CA2294154A1 (en) 1998-12-30
DE69835965D1 (de) 2006-11-02
EP1051191B1 (en) 2006-09-20
CN1261286A (zh) 2000-07-26
US20070292440A1 (en) 2007-12-20
CN1651919A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
DE69835965T2 (de) CD154-BLOCKADETHERAPIE DER PANKREASINSELZELLTRANSPLANTATION bei Primaten
DE69733960T2 (de) Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation
DE69533984T2 (de) Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat
JPH10501815A (ja) 抗原特異的ｔ細胞応答の阻害方法
JP2002502824A (ja) 同種移植における補刺激遮断および混合キメラ現象
US20030170239A1 (en) Immunotherapeutic method to prevent islet cell rejection
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
US8277811B2 (en) Compositions and methods for inducing chimerism in a subject
DE69928407T2 (de) Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten
US20220340672A1 (en) Tnfrsf25-mediated treatments of immune diseases and disorders
EP1754490A2 (en) CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
DE69431184T2 (de) Ein thymus-fremdtransplantat
EP1015016A1 (en) Methods and compositions for preventing autoimmune disease
HK1033548B (en) Cd154 blockade therapy for pancreatic islet tissue transplantation in primates
WO1999045958A1 (en) Cd154 blockade therapy for modulation of immune responses to implanted devices
PL191122B1 (pl) Zastosowania przerywacza wiązania CD40:CD154
CZ461699A3 (cs) Použití činidla rušícího vazbu CD40:CD154 pro přípravu léku k zabránění odhojení štěpu tkáně tvořící inzulín
Tzakis et al. Frequency of kidney rejection in diabetic patients undergoing simultaneous kidney and pancreatic islet cell transplantation
Bloom et al. Costimulation Blockade
MXPA99011740A (en) Cd154 blockade therapy for pancreatic islet tissue transplantation
CA2276733A1 (en) Methods and compositions for preventing autoimmune disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee